This site uses cookies. By using this site you agree to receiving cookies. View Policy.

247%

Active Needle is dedicated to exploiting the properties of ultrasonically Active Needles. The technology allows the products to have potential applications in a range of multi-billion pound markets. These global markets could include healthcare and life sciences & medical and non-medical tattooing.

  • Medical CE mark achieved on first medical product
  • Grant funding of £222k for a £495k tattoo project recently awarded
  • Project sponsored by AstraZeneca, Glaxo & University of Sheffield to produce a device for pre-clinic
  • Highly experienced team with proven healthcare experience
Information £56,912 of funds on the progress bar represent funds raised by the Company prior to launching the campaign. The Company has already received these funds, shares have been issued, and the Company has indicated this may be spent whilst the pitch is live. Completion of the Crowdcube raise will occur on the same material terms and share price

Idea

We believe ultrasonic energy can convey amazing properties to needles. Active Needle Technology (ANT) is dedicated to the exploitation of these properties. Our team of experienced professionals have helped develop a range of products in multi-billion pound markets. In medicine, life science and veterinary applications, ultrasonically energised needles could convey improved visibility for needles in scans. In tattooing, ultrasonic needles may have the potential to reduce pain and swelling.

The company’s lead medical product, a biopsy system, recently received CE mark, which opens the way to sales. Patent grants in China, Japan, and South Korea have been achieved, with others pending.

Development is nearing completion on the company’s life science needle which was developed with the support of AstraZeneca, GlaxoSmithKline and the University of Sheffield. We are in early stage discussions over a distribution partnership.

ANT has recently won a UK grant competition for £220k to productionize, what we believe, is the world’s first ultrasonic tattoo machine. The patent for this product has now been filed in numerous countries.

Poised on the edge of commercialisation, the company is now ready for sales. For investors, the opportunity is to join an exciting, market-ready company with patented, potentially game-changing devices aiming to enter high-value international markets.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the Active Needle Technology Ltd pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered?
Log in

This pitch is approved by Crowdcube

This pitch is approved as a financial promotion by Crowdcube Capital Limited. Every pitch on Crowdcube is reviewed to ensure it is fair, clear and not misleading.

As part of our commitment to investor transparency, Crowdcube’s Due Diligence Charter outlines the analysis and verification that is conducted on equity fundraises on Crowdcube by our legal and compliance professionals.

Read more

Risk warning

Investing in start-ups and early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. Crowdcube is targeted exclusively at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. You will only be able to invest via Crowdcube once you are registered as sufficiently sophisticated. Please click here to read the full Risk Warning.

Crowdcube is authorised and regulated by the Financial Conduct Authority (FCA) and the Comisión Nacional del Mercado de Valores (CNMV). This page has been approved by Crowdcube. Pitches for investment are not offers to the public and investments can only be made by members of crowdcube.com on the basis of information provided in the pitches by the companies concerned. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

Active Needle Technology Ltd has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.